Pre-Chemotherapy Exercise Demonstrates Potential to Alleviate Cancer-Related Fatigue

Why It Matters

Reducing fatigue enhances patients' quality of life and may improve treatment adherence, offering a cost‑effective adjunct to chemotherapy. The findings could shift supportive‑care standards across oncology clinics.

Key Takeaways

• Pre‑chemo exercise cut fatigue scores by 30%.
• 12‑week program improved patients' functional capacity.
• Study involved 150 early‑stage cancer patients.
• No adverse events reported during exercise regimen.
• Findings support integrating physiotherapy into oncology protocols.

Pulse Analysis

Cancer‑related fatigue remains one of the most debilitating side effects of chemotherapy, affecting up to 80% of patients and often limiting treatment intensity. Traditional management relies on pharmacologic agents and counseling, yet evidence increasingly points to physical activity as a potent, low‑risk countermeasure. By positioning exercise before the onset of chemotherapy, clinicians can pre‑empt fatigue rather than merely reacting to it, aligning with a proactive, patient‑centered care model.

The trial, funded by the Society of Nuclear Medicine and Molecular Imaging’s Mars Shot Research Fund, enrolled 150 adults diagnosed with early‑stage solid tumors. Participants engaged in thrice‑weekly, moderate‑intensity aerobic and resistance sessions for 12 weeks prior to their first chemotherapy cycle. Fatigue was quantified using the Brief Fatigue Inventory, revealing a mean reduction of 30% compared with a control group receiving standard care. Functional capacity, measured by the 6‑minute walk test, improved by an average of 12%, and no exercise‑related injuries were reported, underscoring the regimen’s safety and feasibility in a clinical setting.

These results carry significant implications for oncology practice. Integrating pre‑treatment physiotherapy could lower supportive‑care costs by reducing medication use and hospital readmissions linked to severe fatigue. Moreover, the enhanced functional status may enable patients to tolerate more aggressive chemotherapy regimens, potentially improving survival outcomes. Future research should explore optimal exercise dosing, long‑term benefits, and scalability across diverse cancer types, paving the way for evidence‑based guidelines that embed physical activity into the standard oncology treatment algorithm.